Literature DB >> 28360581

Prophylactic Treatment of Migraine.

Azize Esra Gürsoy1, Mustafa Ertaş2.   

Abstract

Migraine is a common chronic neurological disease characterized by episodic attacks of headache and associated symptoms. The pharmacological treatment of migraine may be acute or prophylactic, and patients with frequent, severe headaches often require both approaches. Prophylactic treatment is used to reduce the frequency, duration, or severity of attacks, to enhance the benefits of acute treatments, and to improve patient's ability to function normally. Prophylactic treatment may also prevent progression from episodic migraine to chronic migraine and may result in reductions in health-care cost. The currently available pharmacological options for migraine prophylaxis include a wide array of medications. The major medication groups for prophylactic treatment include β-blockers, anticonvulsant, drugs such as topiramate and valproate, antidepressant drugs, such as amitriptyline and selective serotonin and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), calcium channel antagonists and neurotoxins. The agent for prophylactic treatment should be chosen based on the efficacy and side-effect profile of the drug, and the patient's coexistent and comorbid conditions.

Entities:  

Keywords:  Migraine; prophylactic treatment

Year:  2013        PMID: 28360581      PMCID: PMC5353075          DOI: 10.4274/npa.y7199

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  65 in total

Review 1.  Prophylactic migraine therapy: mechanisms and evidence.

Authors:  Nabih M Ramadan
Journal:  Curr Pain Headache Rep       Date:  2004-04

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects.

Authors:  J R Couch; D K Ziegler; R Hassanein
Journal:  Neurology       Date:  1976-02       Impact factor: 9.910

4.  Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy.

Authors:  Abouch Valenty Krymchantowski; Carla da Cunha Jevoux
Journal:  Headache       Date:  2011-11-15       Impact factor: 5.887

Review 5.  Preventive migraine treatment.

Authors:  Stephen D Silberstein
Journal:  Neurol Clin       Date:  2009-05       Impact factor: 3.806

6.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

7.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

9.  Efficacy of lisinopril in migraine prophylaxis--an open label study.

Authors:  S Schuh-Hofer; U Flach; A Meisel; H Israel; U Reuter; G Arnold
Journal:  Eur J Neurol       Date:  2007-06       Impact factor: 6.089

10.  Propranolol plasma levels and relief of migraine. Relationship between plasma propranolol and 4-hydroxypropranolol concentrations and clinical effects.

Authors:  P Cortelli; T Sacquegna; F Albani; A Baldrati; R D'Alessandro; A Baruzzi; E Lugaresi
Journal:  Arch Neurol       Date:  1985-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.